Cigna Group delivered strong full-year 2025 results, with adjusted revenue growing 11% to $275 billion and adjusted EPS increasing 9% to $29.84, driven by robust performance in its Specialty and Care Services segment. The company announced a comprehensive $7 billion settlement with the FTC regarding its pharmacy benefits business and successfully navigated the passage of federal PBM reform legislation, removing significant regulatory overhangs. Looking ahead to 2026, Cigna provided guidance for adjusted EPS of at least $30.25 and revenue of approximately $280 billion, reflecting confidence in its new 'rebate-free' pharmacy benefit model despite near-term investments and a projected 1% headwind from moving its GPO operations from Switzerland to the US.
| Metric | Value | Change |
|---|---|---|
| Full Year 2025 Adjusted Revenue | $275 billion | +11% year-over-year |
| Full Year 2025 Adjusted EPS | $29.84 | +9% year-over-year |
| Q4 EverNorth Revenue | $63.1 billion | Strong growth driven by Specialty & Care Services (+14%) |
| Q4 Cigna Healthcare Pretax Adjusted Earnings | $734 million | Slightly exceeded expectations |
| 2026 Adjusted EPS Guidance | At least $30.25 | Implies modest growth vs 2025 |
| 2026 Cash Flow from Operations Guidance | Approximately $9 billion | Down from $9.6 billion in 2025 |
| Debt-to-Capitalization Ratio | 43% | Improved 190 basis points in Q4 2025 |
Cigna is executing a strategic pivot in its Pharmacy Benefit Services (PBS) business to a 'rebate-free,' transparent, fee-based model. This shift is designed to align with new federal regulations and the FTC settlement, moving away from traditional spread pricing and rebates. Management emphasized that this model, which guarantees the lowest net cost at the counter, will be the standard offering by 2028, with the Cigna Healthcare fully insured book adopting it by 2027. This signals a proactive attempt to secure market leadership in a reformed PBM landscape.
The company is aggressively reshaping its portfolio towards higher-growth areas, specifically Specialty and Care Services. This segment grew revenue by 14% year-over-year in 2025 and now contributes approximately 35% of the company's income, up from 25% three years ago. Strategic investments, such as the acquisition of Shields Health Solutions, are expanding capabilities to serve hospitals and health systems, positioning Cigna to capture secular growth in specialty pharmaceuticals and biosimilars.
Cigna is leveraging the biosimilar wave as a key strategic differentiator. With over $100 billion in savings expected in the US biosimilar market by 2030, Cigna is positioning itself to drive adoption through initiatives like $0 out-of-pocket offerings for Humira and Stellara. This focus on biosimilars and specialty generics is central to their affordability strategy and creates a competitive moat around their ability to manage drug costs for clients.
The resolution of the FTC investigation and the passage of PBM reform legislation represent a major de-risking event for the company. By settling for $7 billion in out-of-pocket relief over ten years and agreeing to move their GPO operations from Switzerland to the US, Cigna has removed a significant legal overhang. This clarity allows management to focus capital and resources on executing their new business model rather than litigating past practices.
The relocation of the GPO capabilities from Switzerland to the US introduces a tangible financial headwind. Management acknowledged this move could increase the effective tax rate by up to 1% if unmitigated. While they deem this manageable against their 10-14% growth algorithm, it represents a structural increase in the tax burden that will pressure net income margins.
The Cigna Healthcare segment faced margin pressure in the fourth quarter, with medical costs running approximately 60 basis points higher than expected, equating to about $50 million. Management attributed this to an elevated cost trend environment and guided for a 2026 Medical Care Ratio (MCR) of 83.7% to 84.7%, suggesting that medical inflation remains a persistent threat to profitability in the insurance segment.
Operating cash flow is projected to decline in 2026, guided to approximately $9 billion compared to $9.6 billion achieved in 2025. Management attributed this decline to lower contributions from the PBS business due to large client renewals and necessary investments. This contraction in cash generation during a year of heavy transition investment could limit financial flexibility.
There is execution risk associated with the transition to the new PBM model. While management claims the margin profile will remain similar, the shift to a fee-based structure delinked from drug price spread represents a fundamental change in the economics of the business. The success of this model relies heavily on rapid client adoption (50% by 2028) and the ability to monetize clinical services effectively.
Overall: Management exhibited a tone of resolute confidence and strategic clarity throughout the call. David Cordani and his team appeared unshaken by the significant regulatory shifts, framing the FTC settlement and new legislation as a validation of their strategic pivot towards a transparent, rebate-free PBM model. There was no defensiveness; instead, they leaned into the 'dynamic environment,' emphasizing their ability to evolve and lead industry transformation.
Confidence: HIGH - Management consistently used definitive language regarding their financial targets and strategic direction. They reaffirmed their long-term growth algorithm of 10-14% and stated the margin profile of the PBM business would remain 'similar' despite the business model overhaul, indicating high conviction in their execution capabilities.
Management expects at least $30.25 per share. This includes the impact of the new PBM model investments and the GPO relocation. Seasonality is expected to be consistent with prior years, with Q1 EPS slightly above 25% of the full-year total.
Revenue is projected to be approximately $280 billion, representing roughly 1.8% growth over 2025 levels.
EverNorth adjusted earnings are expected to be at least $6.9 billion. Earnings seasonality will shift, with Q1 representing over 20% of the full-year total due to the timing of investments in the new PBM model.
Adjusted earnings are expected to be at least $4.5 billion. The Medical Care Ratio (MCR) is guided in the range of 83.7% to 84.7%, reflecting an elevated cost trend environment and pricing actions taken in stop-loss and individual businesses.
Expected to be approximately 19%. This includes the potential impact of moving the GPO to the US, which could add up to 1% to the rate if unmitigated.
Hedging & Uncertainty: Management generally used direct and confident language, particularly regarding the strategic alignment of their new PBM model with regulatory changes. However, they employed hedging when discussing the financial impacts of the transition and the GPO move. Phrases like 'if unmitigated' regarding the tax rate and 'we expect' or 'approximately' regarding 2026 targets provided room for maneuverability. Notably, when pressed on margin sustainability, David Cordani used the qualifier 'we believe' to maintain flexibility without committing to hard numbers for the future state of the PBM margins.
"We are moving forward with purpose and conviction to counter these forces." - David Cordani, Chairman and CEO
"The settlement is a comprehensive resolution of all matters brought by the FTC regarding our pharmacy benefits business." - David Cordani, Chairman and CEO
"We expect full-year 2026 consolidated adjusted income from operations of at least $30.25 per share." - Ann Dennison, CFO
"We believe the margin profile will remain similar." - David Cordani, Chairman and CEO
"We expect at least 50% of our EverNorth business will adopt the model by year-end 2028." - Brian Evanko, President and COO
Analyst Sentiment: Analysts were highly focused on the financial mechanics of the FTC settlement and the new PBM legislation. Questions from firms like JPMorgan, Goldman Sachs, and Barclays were probing and specific, seeking clarity on margin profiles, tax rates, and revenue recognition changes. There was a tone of skepticism regarding the sustainability of margins in the new transparent model, but also relief that the regulatory uncertainty was resolved.
Management Responses: Management responses were consistent and rehearsed, effectively parrying concerns about margin erosion by reiterating that the 'growth algorithm' remains intact. They were transparent about the 1% tax headwind but dismissed it as manageable. When pressed on specific financial mechanics (e.g., revenue recognition), they provided direct answers or offered to take them offline, maintaining a composed demeanor.
PBM Model Economics & Margins: Analysts sought confirmation that the new rebate-free model would sustain historical profitability. Management affirmed that the margin profile would remain 'similar' despite the shift from spread/revenue to fee-based income.
FTC Settlement & Tax Impact: The financial implications of the $7B settlement and the relocation of the GPO from Switzerland to the US were a major focus. Management clarified the tax rate could rise by up to 1% but emphasized the long-term strategic alignment.
Medical Cost Trends & MCR: Analysts inquired about the elevated medical costs in Q4 and the lack of MCR improvement in 2026 guidance. Management explained the 'one-time items' in 2025 and the prudence built into 2026 assumptions regarding trend.
Client Adoption Rates: There was significant interest in the ramp of the new PBM model. Management confirmed the timeline (Cigna Healthcare in 2027, 50% of EverNorth by 2028) and noted positive early feedback from brokers.
Cigna Group presents a compelling investment opportunity following the resolution of significant regulatory overhangs. The company has successfully pivoted its strategy to align with the new reality of PBM reform, transitioning to a transparent, rebate-free model that should secure its competitive position. The core earnings engine remains robust, with the Specialty and Care Services segment delivering 14% revenue growth and the EverNorth platform showing resilience. While 2026 guidance for EPS of at least $30.25 implies modest growth, this appears to be a conservative 'hold' year during the PBM transition. The removal of legal risk and the clarity provided by federal legislation allow investors to focus on the fundamentals. Key success factors include the successful execution of the new PBM model adoption and maintaining medical cost ratios within the guided range. Risks involve the 1% tax headwind from the GPO repatriation and potential execution stumbles during the business model transformation. However, the valuation likely reflects these risks, and the company's strong cash flow generation ($9.6B in 2025) supports the dividend and share repurchase program. The strategic shift towards higher-growth specialty markets and the affirmation of the long-term 10-14% growth algorithm provide a positive backdrop for the stock.
The PBM industry is undergoing a forced structural shift towards transparency and fee-based models. The passage of federal PBM reform legislation and the aggressive stance of the FTC signal the end of the 'spread pricing' and opaque rebate era. Cigna's proactive settlement and model redesign indicate that the entire sector must adapt to a 'customer-first' standard where value is demonstrated through lower net costs rather than rebate arbitrage.
Medical cost trends remain elevated across the sector. Cigna noted that 'the cost of a hospital stay has increased more than 220% since 2000' and that chronic disease accounts for 90% of spending. This persistent inflationary pressure is forcing insurers to implement strict pricing discipline and optimize site-of-care utilization to maintain margins.
The adoption of biosimilars is accelerating, creating a massive deflationary force in drug spending. With over $100 billion in savings expected by 2030 and the successful penetration of Humira biosimilars, the market is moving rapidly towards competition. PBM's ability to drive this shift is now a critical value proposition for clients.